Capricor Therapeutics (CAPR) Net Equity Issued and Repurchased (2013 - 2025)

Capricor Therapeutics' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $77.5 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased fell 4.13% year-over-year to $77.5 million in Q4 2025; TTM through Dec 2025 was $175.3 million, a 75.12% increase from a year earlier, with the FY2025 full-year figure at $237.0 million, up 55.61% from the prior year.
• Net Equity Issued and Repurchased declined to $77.5 million in Q4 2025 per CAPR's latest filing, from $80.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $80.8 million in Q4 2024 and bottomed at $221081.0 in Q3 2023.
• The 5-year median for Net Equity Issued and Repurchased is $5.2 million (2021), against an average of $17.0 million.
• Across the five-year window, Net Equity Issued and Repurchased plunged 96.53% in 2021 and surged 6684.84% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $7.5 million in 2021, then sank by 61.02% to $2.9 million in 2022, then jumped by 692.41% to $23.2 million in 2023, then surged by 248.99% to $80.8 million in 2024, then retreated by 4.13% to $77.5 million in 2025.
• Per Business Quant, the three latest CAPR Net Equity Issued and Repurchased figures stand at $77.5 million (Q4 2025), $80.8 million (Q4 2024), and $15.0 million (Q3 2024).